Batiraxcept

Summary

Batiraxcept (CHEMBL4594462) is a phase-3 clinical-stage protein; indicated across 7 conditions including ovarian cancer and ovarian neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 7 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594462
Name	Batiraxcept
Type	Protein
Max phase	3

Also known as: AVB S6 500, AVB-500, AVBS6500, Aravive-S6, Batiraxcept, Ruga-S6, BATIRAXCEPT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ovarian cancer	3	MONDO:0008170	MONDO:0008170
ovarian neoplasm	3	MONDO:0021068	EFO:0003893
IgA glomerulonephritis	2	MONDO:0005342	EFO:0004194
clear cell renal carcinoma	1	MONDO:0005005	EFO:0000349
urothelial carcinoma	1	MONDO:0040679	EFO:0008528
neoplasm	1	MONDO:0005070	EFO:0000616
uterine cancer	1	MONDO:0002715	MONDO:0002715

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1	5
PHASE1/PHASE2	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04729608	PHASE3	TERMINATED	Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT04019288	PHASE1/PHASE2	TERMINATED	AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04042623	PHASE2	TERMINATED	Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
NCT04300140	PHASE1/PHASE2	TERMINATED	Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04983407	PHASE1/PHASE2	TERMINATED	Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
NCT04004442	PHASE1	ACTIVE_NOT_RECRUITING	Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
NCT03401528	PHASE1	COMPLETED	A Phase 1 AVB-S6-500 Safety and Tolerability Study
NCT03607955	PHASE1	WITHDRAWN	Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
NCT03639246	PHASE1	COMPLETED	Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT05826015	PHASE1	WITHDRAWN	AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).